UK-based biotechnology company Emergex Vaccines has reported ‘promising’ data from the Phase I naNO-COVID trial of CoronaTcP.

The CoronaTcP drug is designed to treat Betacoronaviruses such as SARS-CoV-1 and emerging variants of SARS-CoV-2, the virus that causes Covid-19.

The randomised, double-blind study was conducted at Centre Hospitalier Universitaire Vaudois, which is part of the University of Lausanne in Switzerland.

It was part of a two-stage clinical trial and was initiated based on safety data from an interim analysis of the first stage, which was named naNO-DENGUE.

The naNO-COVID study assessed the safety and reactogenicity of low-dose 2.5nmol CoronaTcP and high-dose 7.5nmol in healthy adults.

A total of 26 healthy adult volunteers who were previously vaccinated against SARS-CoV-2 were administered intradermally with different dosages using a microneedle device.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Each participant received the assigned treatment on days zero and 21. The treatments were then followed up for a further six months.

CoronaTcP demonstrated a favourable safety profile and did not cause any serious adverse events in the trial.

Despite this, mild adverse events were observed in 88% of participants, with injection-site pain being the most common.

In terms of overall safety or reactogenicity, no systematic difference between the two treatment groups was found.

Memory CD8+ T-cells were activated in patients treated with two dosages and at Day 35 post-treatment, an increase in frequencies of CoronaTcP-specific CD8+ CD137+ CD69+ cells was also observed.

Emergex Vaccines co-founder and CEO Thomas Rademacher said: “Demonstrating that our platform has an acceptable safety profile and successfully mobilises specific T-cells that may elicit broad and long-term immune memory, validates our approach.

“By improving T-cell-based immunity, we can enhance any previous immune status.

“We are delighted that this first assessment of a treatment against infectious diseases for clinical use, based solely on a T-cell response, was successful.”